Smart AFO + 5-Azacitidine for Cerebral Palsy

This trial explores how a smart ankle-foot orthosis (AFO) can improve mobility in children with cerebral palsy. Participants will use the smart AFO at home for six weeks. Some will also try 5-azacitidine, a chemotherapy drug, to determine if it enhances the AFO's effects. The study seeks children with cerebral palsy who can walk for at least six minutes (even with assistance) and have caregiver support for training sessions. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to important findings.

The trial information does not specify if you need to stop taking your current medications. However, if you have a new implanted device or are undergoing active medication titration, you may not be eligible. It's best to discuss your specific medications with the study team.

Previous studies have shown that smart ankle-foot orthoses (AFOs) are well-tolerated in children with cerebral palsy. These devices often assist with walking and correcting foot alignment. Although the smart AFO in this trial remains experimental, similar devices have not presented major safety issues in past research.

5-Azacitidine, another component of this study, is a drug already approved by the FDA for other uses, indicating general safety. For children with blood disorders, a dose of 75 mg/m² of 5-Azacitidine was well-tolerated. Some studies reported mild to moderate side effects, but it has been used safely in children before.

Unlike traditional treatments for cerebral palsy, which often focus on physical therapy and medication to manage symptoms, the Smart Ankle-Foot Orthosis (AFO) offers a new approach by integrating technology into gait training. Researchers are excited about Smart AFO because it provides real-time feedback and encourages active participation in rehabilitation through structured home intervention sessions. Additionally, the introduction of 5-azacitidine, typically used in cancer treatment, as part of the trial is notable because it explores a novel potential mechanism for enhancing neurological function and muscle control in cerebral palsy patients. This combination aims to improve mobility and quality of life in ways that current standard therapies do not.

Studies have shown that ankle-foot orthoses (AFOs) help children with cerebral palsy walk better by improving speed, stride length, and balance. Research suggests that smart AFOs, which are more advanced, might offer additional benefits by maintaining ankle strength while walking. Users of AFOs have experienced better mobility and found walking easier and less tiring.